SCHEMBL550869

SCHEMBL550869

CCOC(=O)C1(CCCl)CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 4/20 0.41
NPC1 O15118 4/20 0.41
MEN1 O00255 3/20 0.41
RAB9A P51151 3/20 0.41
MMP2 P08253 1/20 0.40
MMP13 P45452 1/20 0.40
MMP14 P50281 1/20 0.40
ADAM17 P78536 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HSD11B1 P28845 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20503060 0.90 L3MBTL1 (0.45) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL5428070 0.89 CYP4F2 (0.46) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL4569993 0.88 L3MBTL1 (0.42) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL17082035 0.88 L3MBTL1 (0.42) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL2888789 0.88 L3MBTL1 (0.47) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL21749176 0.86 L3MBTL1 (0.46) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL21749211 0.85 L3MBTL1 (0.45) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL21749194 0.85 L3MBTL1 (0.45) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL12543830 0.85 L3MBTL1 (0.45) L3MBTL1KMT2ANPC1MEN1RAB9A
SCHEMBL3498221 0.85 L3MBTL1 (0.42) L3MBTL1KMT2ANPC1MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812005-B1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2015-09-16 EP disclosed
US-8563570-B2 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2013-10-22 US disclosed
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-05-17 US disclosed
EP-2450351-A1 Lactam compounds and their use as pharmaceuticals Incyte Corporation (US) 2012-05-09 EP disclosed
US-8110581-B2 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-02-07 US disclosed
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2009-11-26 US disclosed
EP-1812005-A2 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-08-01 EP disclosed
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-01 US disclosed
WO-2006053024-A2 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals HSD11B1, HSD11B2, HSD17B1 L3MBTL1 4609/4885KMT2A 3165/4885NPC1 722/4885
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 L3MBTL1 4609/4885KMT2A 3165/4885NPC1 722/4885
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 L3MBTL1 4609/4885KMT2A 3165/4885NPC1 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.